NVO
NOVO NORDISK A S
NYSE: NVO · Bagsvaerd Denmark, G7 · Healthcare
$42.19+1.17 (+2.85%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$34.76 – $77.31
Avg Volume18.1M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$42.19-68.6%
Pipeline
Drug candidates sponsored by NOVO NORDISK A S · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Unnamed | Diabetes+2 more | Completed | 2006-06past | 1 | |
| Phase 4 | insulin detemir | Diabetes+2 more | Completed | 2009-10past | 8 | |
| Phase 4 | repaglinide | Diabetes+1 more | Completed | 2009-11past | 3 | |
| Phase 4 | insulin aspart | Diabetes+3 more | Completed | 2009-11past | 2 | |
| Phase 4 | biphasic insulin aspart 30 | Diabetes+3 more | Completed | 2015-07-09past | 5 | |
| Phase 4 | liraglutide | Diabetes+4 more | Completed | 2017-06-16past | 13 | |
| Phase 3 | biphasic insulin aspart 50 | Diabetes+2 more | Completed | 2001-04past | 1 | |
| Phase 3 | Unnamed | Diabetes+3 more | Completed | 2004-02past | 1 | |
| Phase 3 | biphasic insulin aspart | Diabetes+2 more | Completed | 2004-06past | 2 | |
| Phase 3 | inhaled human insulin | Diabetes+1 more | Completed | 2004-12-14past | 1 | |
| Phase 3 | rosiglitazone | Diabetes+1 more | Terminated | 2008-03-05past | 1 | |
| Phase 3 | insulin degludec/insulin aspart | Diabetes+1 more | Completed | 2010-10past | 1 | |
| Phase 3 | insulin degludec | Diabetes+3 more | Completed | 2012-06past | 4 | |
| Phase 3 | insulin degludec/liraglutide | Diabetes+1 more | Completed | 2014-03-11past | 1 | |
| Phase 3 | Concizumab | Haemophilia A With Inhibitors+1 more | Active, not recruiting | 2021-12-27past | 1 | |
| Phase 3 | Semaglutide J | Diabetes Mellitus, Type 2 | Completed | 2023-08-09past | 1 | |
| Phase 3 | Insulin icodec | Diabetes Mellitus, Type 2 | Completed | 2024-02-08past | 5 | |
| Phase 3 | semaglutide | Diabetes+6 more | Completed | 2025-09-15past | 9 | |
| Phase 3 | Ziltivekimab B | Cardiovascular Risk+2 more | Active, not recruiting | 2026-06-09 | 1 | |
| Phase 3 | NNC0487-0111 | Obesity+2 more | Recruiting | 2028-08-14 | 1 | |
| Phase 2 | activated recombinant human factor VII | Acquired Bleeding Disorder+1 more | Completed | 2002-11past | 1 | |
| Phase 2 | insulin glargine | Diabetes+1 more | Completed | 2008-08past | 1 | |
| Phase 2 | somatropin | Chronic Kidney Disease+3 more | Completed | 2013-11past | 2 | |
| Phase 2 | NNC0365-3769 (Mim8) | Healthy Volunteers+1 more | Completed | 2023-10-06past | 1 | |
| Phase 2 | NNC0662-0419 | Diabetes Mellitus, Type 2 | Recruiting | 2027-09-03 | 1 | |
| Phase 1 | biphasic insulin aspart 70 | Diabetes+1 more | Completed | 2003-02-26past | 1 | |
| Phase 1 | repaglinide and metformin combination tablet | Diabetes+1 more | Completed | 2009-10past | 1 | |
| Phase 1 | NNC 0151-0000-0000 | Inflammation+1 more | Withdrawn | 2009-11past | 1 | |
| Phase 1 | NN1218 | Diabetes+1 more | Completed | 2010-07past | 1 | |
| Phase 1 | catridecacog | Congenital Bleeding Disorder+2 more | Completed | 2010-07past | 1 | |
| Phase 1 | anti-IL-20 | Inflammation+3 more | Completed | 2011-01past | 2 | |
| Phase 1 | NNC 0123-0000-0338 | Diabetes+1 more | Completed | 2011-09-16past | 1 | |
| Phase 1 | NNC0114-0006 | Inflammation+1 more | Terminated | 2014-02past | 1 | |
| Phase 1 | Faster-acting insulin aspart | Diabetes+2 more | Completed | 2017-12-21past | 4 | |
| Phase 1 | turoctocog alfa pegol | Congenital Bleeding Disorder+1 more | Completed | 2018-10-15past | 1 | |
| Phase 1 | NNC9204-1706 | Metabolism and Nutrition Disorder+1 more | Completed | 2019-09-05past | 1 | |
| Phase 1 | NNC0268-0965 | Diabetes Mellitus, Type 2 | Completed | 2020-08-23past | 1 | |
| Phase 1 | Cagrilintide | Obesity | Completed | 2024-10-16past | 1 | |
| Phase 1 | NNC1679-0001 | Healthy Volunteers+1 more | Recruiting | 2028-06-25 | 1 | |
| N/A | Marketed low dose hormone replacement therapy | Menopause+1 more | Completed | 2006-06past | 1 | |
| N/A | Unnamed | Diabetes+2 more | Completed | 2009-04past | 1 | |
| N/A | Unnamed | Diabetes+3 more | Completed | 2009-07past | 1 | |
| N/A | Unnamed | Growth Hormone Disorder+1 more | Withdrawn | 2010-04past | 1 | |
| N/A | eptacog alfa (activated) | Congenital Bleeding Disorder+6 more | Completed | 2010-12past | 2 | |
| N/A | Unnamed | Diabetes+1 more | Completed | 2014-03past | 1 | |
| N/A | Unnamed | Congenital Bleeding Disorder+4 more | Completed | 2014-10past | 1 | |
| N/A | Fiasp® | Diabetes Mellitus, Type 1 | Completed | 2020-12-21past | 1 | |
| N/A | Unnamed | Obesity | Completed | 2022-04-08past | 1 | |
| N/A | Unnamed | Atherosclerotic Cardiovascular Disease (ASCVD)+1 more | Completed | 2024-12-05past | 1 | |
| N/A | IDegLira | Diabetes Mellitus, Type 2 | Completed | 2025-02-23past | 2 | |
| N/A | Somapacitan | Growth Hormone Deficiency in Children | Enrolling | 2026-07-31 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for NVO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.